Compare Elastic NV (ESTC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs GeneDx Holdings Corp — how do they compare? Elastic NV trades at $96.84 (market cap $10.00B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: Elastic NV is far larger — about 5× GeneDx Holdings Corp's market cap, and Elastic NV is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and GeneDx Holdings Corp for 19 Days on average.
| ESTC | WGS | |
|---|---|---|
Market Cap | $10.00B | $2.02B |
Volume | 1,610,337 | 734,640 |
Sector | Technology | Health |
52-Week High | $99.91 | $167.51 |
52-Week Low | $43.30 | $34.51 |
Typical Hold Time | 10 Days | 19 Days |
Enterprise Value | $9.14B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $96.44, up 3.59% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches in AI and observability platforms highlight innovation, while profitability metrics show improvement into 2026. The current price sits near resistance at $97, with RSI indicating potential overbought conditions short-term.
Outlook remains positive given earnings momentum and product expansion, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though bullish sentiment prevails with 65% buy ratings. Investors should weigh growth potential against execution risks in a competitive software market.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
